Page last updated: 2024-09-03

f-chemotactic peptide and trp-lys-tyr-met-val-met

f-chemotactic peptide has been researched along with trp-lys-tyr-met-val-met in 1 studies

Compound Research Comparison

Studies (f-chemotactic peptide)	Trials (f-chemotactic peptide)	Recent Studies (post-2010) (f-chemotactic peptide)	Studies (trp-lys-tyr-met-val-met)	Trials (trp-lys-tyr-met-val-met)	Recent Studies (post-2010) (trp-lys-tyr-met-val-met)
79	0	4	92	1	38

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bylund, J; Dahlgren, C; Fu, H; Karlsson, J; Stenfeldt, AL; Wennerås, C	1

Other Studies

1 other study(ies) available for f-chemotactic peptide and trp-lys-tyr-met-val-met

Article	Year
The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1. Biochemical pharmacology, 2007, Oct-01, Volume: 74, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Humans; Ligands; Neutrophils; Oligopeptides; Piroxicam; Protein Binding; Receptors, Formyl Peptide; Receptors, Lipoxin; Superoxides	2007

Article

Year

The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.

Biochemical pharmacology, 2007, Oct-01, Volume: 74, Issue:7

Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Humans; Ligands; Neutrophils; Oligopeptides; Piroxicam; Protein Binding; Receptors, Formyl Peptide; Receptors, Lipoxin; Superoxides

2007